Richard J Willke

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience
    Richard J Willke
    Global Outcomes Research, Pfizer Inc, Peapack, NJ 07977, USA
    Curr Med Res Opin 24:2873-82. 2008
  2. doi request reprint Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice
    Richard J Willke
    Pfizer, New York, NY, USA Electronic address
    Value Health 16:S10-5. 2013
  3. pmc Lost productivity due to premature mortality in developed and emerging countries: an application to smoking cessation
    Joseph Menzin
    Boston Health Economics, Inc, Waltham, MA 02451, USA
    BMC Med Res Methodol 12:87. 2012
  4. pmc From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer
    Richard J Willke
    Pfizer, Inc, 235 E, 42nd Street, New York, NY 10017, USA
    BMC Med Res Methodol 12:185. 2012
  5. ncbi request reprint Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels
    Richard J Willke
    Pfizer Inc, Bridgewater, NJ 08807, USA
    Control Clin Trials 25:535-52. 2004
  6. doi request reprint Communication about results of comparative effectiveness studies: a pharmaceutical industry view
    Eleanor M Perfetto
    Pfizer Inc, Washington, D C, USA
    Health Aff (Millwood) 31:2213-9. 2012
  7. ncbi request reprint Measuring agreement between patient and proxy responses to multidimensional health-related quality-of-life measures in clinical trials. An application of psychometric profile analysis
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 17969 27715, USA
    J Clin Epidemiol 55:608-18. 2002
  8. ncbi request reprint US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?
    I Chan Huang
    Department of Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville, FL, USA
    Qual Life Res 16:1065-72. 2007
  9. pmc Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease
    I Chan Huang
    Department of Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville, FL, USA
    Health Serv Res 43:327-39. 2008

Collaborators

  • Mark J Cziraky
  • Kevin P Weinfurt
  • Albert W Wu
  • Mark J Atkinson
  • I Chan Huang
  • Joseph Menzin
  • Eleanor M Perfetto
  • Constantine Frangakis
  • Victoria Federico
  • Jordan A Menzin
  • Steven J Romano
  • Norman R Rosenthal
  • Kathleen R Gans-Brangs
  • John E Bailey
  • Rebecca M Woodward
  • Jeno P Marton
  • Walter L Leite
  • W Bruce Vogel
  • William R Lenderking

Detail Information

Publications9

  1. ncbi request reprint Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience
    Richard J Willke
    Global Outcomes Research, Pfizer Inc, Peapack, NJ 07977, USA
    Curr Med Res Opin 24:2873-82. 2008
    ....
  2. doi request reprint Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice
    Richard J Willke
    Pfizer, New York, NY, USA Electronic address
    Value Health 16:S10-5. 2013
    ....
  3. pmc Lost productivity due to premature mortality in developed and emerging countries: an application to smoking cessation
    Joseph Menzin
    Boston Health Economics, Inc, Waltham, MA 02451, USA
    BMC Med Res Methodol 12:87. 2012
    ..The estimation of indirect costs is commonly done on a country-specific basis. However, there are few studies that evaluate indirect costs across countries using a consistent methodology...
  4. pmc From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer
    Richard J Willke
    Pfizer, Inc, 235 E, 42nd Street, New York, NY 10017, USA
    BMC Med Res Methodol 12:185. 2012
    ..By guiding the selection of the methods and analysis, this review is meant to better enable outcomes researchers to understand and explore aspects of HTE in the context of patient-centered outcomes research...
  5. ncbi request reprint Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels
    Richard J Willke
    Pfizer Inc, Bridgewater, NJ 08807, USA
    Control Clin Trials 25:535-52. 2004
    ..This term coincides with the explicit interest from drug development researchers and regulatory authorities in the appropriate utilization and reporting of treatment impact measures...
  6. doi request reprint Communication about results of comparative effectiveness studies: a pharmaceutical industry view
    Eleanor M Perfetto
    Pfizer Inc, Washington, D C, USA
    Health Aff (Millwood) 31:2213-9. 2012
    ....
  7. ncbi request reprint Measuring agreement between patient and proxy responses to multidimensional health-related quality-of-life measures in clinical trials. An application of psychometric profile analysis
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 17969 27715, USA
    J Clin Epidemiol 55:608-18. 2002
    ..Options for incorporating proxy responses into clinical trial analyses are discussed...
  8. ncbi request reprint US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?
    I Chan Huang
    Department of Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville, FL, USA
    Qual Life Res 16:1065-72. 2007
    ..Most US studies that estimate EQ-5D index score generally apply the UK preference weights. We compared the validity of a newly-developed US weights to the UK weights for use of EQ-5D as a measure of health-related quality of life...
  9. pmc Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease
    I Chan Huang
    Department of Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville, FL, USA
    Health Serv Res 43:327-39. 2008
    ..To compare different approaches to address ceiling effects when predicting EQ-5D index scores from the 10 subscales of the MOS-HIV Health Survey...